Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Operating Expenses (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Other Operating Expenses for 8 consecutive years, with $29.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 2090.16% year-over-year to $29.2 million, compared with a TTM value of $131.6 million through Dec 2025, up 2090.21%, and an annual FY2025 reading of $5.9 million, down 0.97% over the prior year.
  • Other Operating Expenses was $29.2 million for Q4 2025 at Karyopharm Therapeutics, down from $32.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $35.9 million in Q1 2025 and bottomed at -$80.3 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is -$3.7 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses crashed 18438.58% in 2021, then skyrocketed 2412.08% in 2025.
  • Year by year, Other Operating Expenses stood at $742000.0 in 2021, then soared by 151.75% to $1.9 million in 2022, then fell by 20.45% to $1.5 million in 2023, then decreased by 10.43% to $1.3 million in 2024, then skyrocketed by 2090.16% to $29.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for KPTI at $29.2 million in Q4 2025, $32.7 million in Q3 2025, and $33.8 million in Q2 2025.